Cardiovascular disease in dialysis patients: Do some antihypertensive drugs have specific antioxidant effects or is it just blood pressure reduction? Does antioxidant treatment reduce the risk for cardiovascular disease?

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 1, 2008, Pages 99-105

  Aslam, Shakil ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b 6PHC ^*  (United States)

Author keywords

Antihypertensives; Antioxidants; Chronic kidney disease; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ARGININE DERIVATIVE; ATORVASTATIN; AZELNIDIPINE; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FELODIPINE; FOSINOPRIL; GLYCERYL TRINITRATE; HYDRALAZINE; LABETALOL; METHYLARGININE; METOPROLOL; NIFEDIPINE; SPIRONOLACTONE; TELMISARTAN; TEMPOL; TRANDOLAPRIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

AMINO ACID BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFECT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INTERVENTION STUDY; KIDNEY FAILURE; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; RENAL DIALYSIS; RISK FACTORS;

EID: 37349109691     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f313bd     Document Type: Review

References (71)

1. U.S. Renal Data System, USRDS 2005 Annual Data Report. Atlas of end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005.
2. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 2003; 63 (Suppl 85):S105-S110.
3. Li Z, Lacson E Jr, Lowrie EG, et al. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis 2006; 48:606-615. This cohort study in patients on hemodialysis reported a reverse J shape relationship between systolic blood pressure and survival.
4. Kilpatrick RD, McAllister CJ, Kovesdy CP, et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007; 18:293-303. This recent cohort study including over 15 000 dialysis patients reported a better survival in patients with a high low density lipoprotein and total cholesterol except among black patients.
5. Kalantar-Zadeh K, Kopple JD. Obesity paradox in patients on maintenance dialysis. Contrib Nephrol 2006; 151:57-69.
6. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164:659-663.
7. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55:1899-1911.
8. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004; 43:1439-1444.
9. Chlebowski RT, Grosvenor M, Lillington L, et al. Dietary intake and counseling, weight maintenance, and the course of HIV infection. J Am Diet Assoc 1995; 95:428-432.
10. Halabi S, Small EJ, Vogelzang NJ. Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005; 23:2434-2435.
11. Escalante A, Haas RW, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005; 165:1624-1629.
12. Zou M, Martin C, Ullrich V. Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biol Chem 1997; 378:707-713.
13. Podrez EA, Poliakov E, Shen Z, et al. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem 2002; 277:38517-38523.
14. Sydow K, Munzel T. ADMA and oxidative stress. Atheroscler Suppl 2003; 4:41-51.
15. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-575.
16. Boger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: Involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87:99-105.
17. Fukui T, Ishizaka N, Rajagopalan S, et al. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997; 80:45-51.
18. Chabrashvili T, Kitiyakara C, Blau J, et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 2003; 285:R117-R124.
19. Kitiyakara C, Chabrashvili T, Chen Y, et al. Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol 2003; 14:2775-2782.
20. Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 2005; 289:R913-R935.
21. Takaya T, Kawashima S, Shinohara M, et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis 2006; 186:402-410.
22. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42:905-910.
23. Aslam S, Santha T, Leone A, Wilcox C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int 2006; 70:2109-2115. A randomized double blind cross-over study examined the antioxidant activity of valsartan and amlodipine in patients on maintenance hemodialysis.
24. Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70:1318-1324. A randomized study of fosinopril in dialysis patients failed to reduce CVD mortality, and poor randomization made it inconclusive.
25. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
26. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
27. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the rennin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366:2026-2033.
28. Virdis A, Neves MF, Amiri F, et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002; 40:504-510.
29. Onozato ML, Tojo A, Kobayashi N, et al. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-{beta} and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant 2007; 22:1314-1322.
30. Takebayashi K, Matsumoto S, Aso Y, Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006; 91:2214-2217.
31. Manabe S, Okura T, Fukuoka T, Higaki J. Antioxidative effects of azelnidipine on mesangial cell proliferation induced by highly concentrated insulin. Eur J Pharmacol 2007; 567:252-257.
32. Nakano K, Egashira K, Ohtani K, et al. Azelnidipine has antiatherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice. Atherosclerosis (in press).
33. Koyama Y, Takeishi Y, Takahashi H, et al. Azelnidipine inhibits H2O2-induced cell death in neonatal rat cardiomyocytes. Cardiovasc Drugs Ther 2007; 21:69-72.
34. Shinomiya K, Mizushige K, Fukunaga M, et al. Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells. J Int Med Res 2004; 32:170-175.
35. Mason RP, Walter MF, Trumbore MW, et al. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1999; 31:275-281.
36. Mason RP, Campbell SF, Wang SD, Herbette LG. Comparison of location and binding for the positively charged 1, 4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes. Mol Pharmacol 1989; 36:634-640.
37. Lenasi H, Kohlstedt K, Fichtlscherer B, et al. Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495. Cardiovasc Res 2003; 59:844-853.
38. Hasegawa H, Takano H, Kohro T, et al. Amelioration of hypertensive heart failure by amlodipine may occur via antioxidative effects. Hypertens Res 2006; 29:719-729.
39. Manabe S, Okura T, Fukuoka T, Higaki J. Antioxidative effects of azelnidipine on mesangial cell proliferation induced by highly concentrated insulin. Eur J Pharmacol 2007; 567:252-257.
40. Yamagishi S, Inagaki Y, Kikuchi S. Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation. Drugs Exp Clin Res 2003; 29:147-152.
41. Arumanayagam M, Chan S, Tong S, Sanderson JE. Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. J Cardiovasc Pharmacol 2001; 37:48-54.
42. Book WM. Carvedilol: a nonselective beta blocking agent with antioxidant properties. Congest Heart Fail 2002; 8:173-177; 190.
43. Maggi E, Marchesi E, Covini D, et al. Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 1996; 27:532-538.
44. Dandona P, Karne R, Ghanim H, et al. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000; 101:122-124.
45. Feuerstein G, Yue TL, Ma X, Ruffolo RR. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 1998; 41:17-24.
46. Christopher TA, Lopez BL, Ma XL, et al. Effects of a hydroxylated metabolite of the β-adrenoreceptor antagonist, carvedilol, on postischaemic splanchnic tissue injury. Br J Pharmacol 1998; 123:292-298.
47. Ma XL, Gao F, Nelson AH, et al. Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. J Pharmacol Exp Ther 2001; 298:879-885.
48. Nakamura K, Kusano K, Nakamura Y, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002; 105:2867-2871.
49. Bakris GL, Fonseca V, Katholi RE, et al., for the GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227-2236.
50. Münzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995; 95:187-194.
51. Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 1995; 26:1575-1580.
52. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314:1547-1552.
53. Taylor AL, Ziesche S, Yancy C, et al., the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351:2049-2057.
54. Yang CC, Hsu SP, Wu MS, et al. Effects of vitamin C infusion and vitamin E-coatedmembrane on hemodialysis-induced oxidative stress. Kidney Int 2006; 69:706-714.
55. Morimoto H, Nakao K, Fukuoka K, et al. Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients. Nephrol Dial Transplant 2005; 20:2775-2782.
56. Betjes MG, Hoekstra FM, Klepper M, et al. Vitamin E-coated dialyzer membranes downregulate expression of monocyte adhesion and co-stimulatory molecules. Blood Purif 2004; 22:510-517.
57. Kobayashi S, Moriya H, Aso K, Ohtake T. Vitamin E-bonded hemodialyzer improves atherosclerosis associated with a rheological improvement of circulating red blood cells. Kidney Int 2003; 63:1881-1887.
58. Pertosa G, Grandaliano G, Soccio M, et al. Vitamin E-modified filters modulate Jun N-terminal kinase activation in peripheral blood mononuclear cells. Kidney Int 2002; 62:602-610.
59. Tsuruoka S, Kawaguchi A, Nishiki K, et al. Vitamin E-bonded hemodialyzer improves neutrophil function and oxidative stress in patients with end-stage renal failure. Am J Kidney Dis 2002; 39:127-133.
60. Clermont G, Lecour S, Cabanne JF, et al. Vitamin E-coated dialyzer reduces oxidative stress in hemodialysis patients. Free Radic Biol Med 2001; 31:233-241.
61. Omata M, Higuchi C, Demura R, et al. Reduction of neutrophil activation by vitamin E modified dialyzer membranes. Nephron 2000; 85:221-231.
62. Tarng DC, Huang TP, Liu TY, et al. Effect of vitamin E-bonded membrane on the 8-hydroxy 2′-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney Int 2000; 58:790-799.
63. Mune M, Yukawa S, Kishino M, et al. Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney Int Suppl 1999; 71:S126-S129.
64. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356:1213-1218.
65. Hodkova M, Dusilova-Sulkova S, Kalousova M, et al. Influence of oral vitamin E therapy on micro-inflammation and cardiovascular disease markers in chronic hemodialysis patients. Ren Fail 2006; 28:395-399.
66. Uzum A, Toprak O, Gumustas MK, et al. Effect of vitamin E therapy on oxidative stress and erythrocyte osmotic fragility in patients on peritoneal dialysis and hemodialysis. J Nephrol 2006; 19:739-745.
67. Diepeveen SH, Verhoeven GW, Van Der PJ, et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. J Intern Med 2005; 257:438-445.
68. Roob JM, Khoschsorur G, Tiran A, et al. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000; 11:539-549.
69. Ono K. Effects of large dose vitamin E supplementation on anemia in hemodialysis patients. Nephron 1985; 40:440-445.
70. Sinsakul V, Drake JR, Leavitt JN Jr, et al. Lack of effect of vitamin E therapy on the anemia of patients receiving hemodialysis. Am J Clin Nutr 1984; 39:223-226.
71. Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107:992-995.